French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance
Tóm tắt
Từ khóa
Tài liệu tham khảo
Oefelein, 2000, Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making, Urology, 56, 2021, 10.1016/S0090-4295(00)00793-7
Bourke, 2015, Survivorship and improving quality of life in men with prostate cancer, Eur Urol, 68, 374, 10.1016/j.eururo.2015.04.023
Bourke, 2016, Exercise for men with prostate cancer: a systematic review and meta-analysis, Eur Urol, 69, 693, 10.1016/j.eururo.2015.10.047
Resnick, 2015, Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement, J Clin Oncol, 33, 1078, 10.1200/JCO.2014.60.2557
Greenspan, 2013, Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy, J Bone Miner Res, 28, 325, 10.1002/jbmr.1771
Morote, 2007, Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer, Urology, 69, 500, 10.1016/j.urology.2006.11.002
Briot, 2019, French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation, Joint Bone Spine, 86, 21, 10.1016/j.jbspin.2018.09.017
Irani, 2010, Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial, Lancet Oncol, 11, 147, 10.1016/S1470-2045(09)70338-9
Mottet, 2006, Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer, BJU Int, 98, 20, 10.1111/j.1464-410X.2006.06176.x
Galvao, 2021, Exercise medicine in men with prostate cancer: breaking barriers to increase participation, Prostate Cancer Prostatic Dis, 24, 942, 10.1038/s41391-021-00406-4
Clement, 1996, Utilization of the Draw a Person Test in the elderly, Int Psychogeriatr, 8, 349, 10.1017/S1041610296002724
Borson, 2003, The Mini-Cog as a screen for dementia: validation in a population-based sample, J Am Geriatr Soc, 51, 1451, 10.1046/j.1532-5415.2003.51465.x
Basaria, 2006, Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy, Cancer, 106, 581, 10.1002/cncr.21642
Malkin, 2004, The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men, J Clin Endocrinol Metab, 89, 3313, 10.1210/jc.2003-031069
Bhatia, 2016, Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer, Circulation, 133, 537, 10.1161/CIRCULATIONAHA.115.012519
Maluf, 2021, A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415), Eur J Cancer, 158, 63, 10.1016/j.ejca.2021.08.032
Ohlmann, 2022, LHRH sparing therapy in patients with chemotherapy-naive, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial, Prostate Cancer Prostatic Dis, 10.1038/s41391-022-00533-6
Romero-Laorden, 2018, Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study), Br J Cancer, 119, 1052, 10.1038/s41416-018-0123-9
Smith, 2021, Apalutamide and overall survival in prostate cancer, Eur Urol, 79, 150, 10.1016/j.eururo.2020.08.011
James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5
Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458
Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6
Smith, 2015, Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, Ann Oncol, 26, 368, 10.1093/annonc/mdu519
Smith, 2012, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, Lancet, 379, 39, 10.1016/S0140-6736(11)61226-9
Smith, 2019, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 408, 10.1016/S1470-2045(18)30860-X
Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755
Sartor, 2014, Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial, Lancet Oncol, 15, 738, 10.1016/S1470-2045(14)70183-4
Benesova, 2015, Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer, J Nucl Med, 56, 914, 10.2967/jnumed.114.147413
Ahmadzadehfar, 2020, PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients, Semin Nucl Med, 50, 98, 10.1053/j.semnuclmed.2019.07.003
Kratochwil, 2019, EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT), Eur J Nucl Med Mol Imaging, 46, 2536, 10.1007/s00259-019-04485-3
Sartor, 2021, Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer, N Engl J Med, 385, 1091, 10.1056/NEJMoa2107322
Hofman, 2018, [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study, Lancet Oncol, 19, 825, 10.1016/S1470-2045(18)30198-0
Rahbar, 2017, German Multicenter Study Investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients, J Nucl Med, 58, 85, 10.2967/jnumed.116.183194
Kratochwil, 2018, Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control, J Nucl Med, 59, 795, 10.2967/jnumed.117.203539
Barber, 2019, Clinical Outcomes of (177)Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy, J Nucl Med, 60, 955, 10.2967/jnumed.118.216820
Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294
Beer, 2017, Randomized, Double-Blind, Phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol, 35, 40
Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol, 15, 700, 10.1016/S1470-2045(14)70189-5
Fizazi, 2020, Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors, Eur Urol, 78, 822, 10.1016/j.eururo.2020.07.032
Antonarakis, 2020, CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase Inhibitors, and PD-1 inhibitors, JCO Precis Oncol, 4, 370, 10.1200/PO.19.00399
Powles, 2022, Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial, Nat Med, 28, 144, 10.1038/s41591-021-01600-6
Sharma, 2020, Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 Trial, Cancer Cell., 38, 10.1016/j.ccell.2020.08.007
Hussain, 2020, Survival with olaparib in metastatic castration-resistant prostate cancer, N Engl J Med, 383, 2345, 10.1056/NEJMoa2022485
Teyssonneau, 2022, PARP Inhibitors as monotherapy in daily practice for advanced prostate cancers, J Clin Med, 11, 1734, 10.3390/jcm11061734
Ploussard, 2022, [DNA repair gene alterations testing in prostate cancer: a practical update by the prostate cancer committee of the french association of urology], Prog Urol, 32, 155, 10.1016/j.purol.2021.12.007
Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 162, 454, 10.1016/j.cell.2015.06.053
Carver, 2011, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer, Cancer Cell, 19, 575, 10.1016/j.ccr.2011.04.008
de Bono, 2019, Randomized Phase II Study Evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN Loss, Clin Cancer Res, 25, 928, 10.1158/1078-0432.CCR-18-0981
Sweeney, 2021, Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial, Lancet, 398, 131, 10.1016/S0140-6736(21)00580-8
Gasmi, 2021, Overview of the development and use of akt inhibitors in prostate cancer, J Clin Med, 11, 160, 10.3390/jcm11010160
Francini, 2018, Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC), Prostate, 78, 889, 10.1002/pros.23645
Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol, 20, 686, 10.1016/S1470-2045(19)30082-8
Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747
Buelens, 2018, Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial, Urol Oncol, 36, 10.1016/j.urolonc.2017.12.009
Foster, 2019, Oligometastatic prostate cancer: reality or figment of imagination?, Cancer, 125, 340, 10.1002/cncr.31860
Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1
Reyes, 2015, The biology and treatment of oligometastatic cancer, Oncotarget, 6, 8491, 10.18632/oncotarget.3455
Albertsen, 2014, Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist, Eur Urol, 65, 565, 10.1016/j.eururo.2013.10.032
Margel, 2019, Cardiovascular morbidity in a randomized trial comparing GnRH Agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease, J Urol, 202, 1199, 10.1097/JU.0000000000000384
Lopes, 2021, Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial, Circulation, 144, 1295, 10.1161/CIRCULATIONAHA.121.056810
Shore, 2020, Oral relugolix for androgen-deprivation therapy in advanced prostate cancer, N Engl J Med, 382, 2187, 10.1056/NEJMoa2004325
Kunath, 2014, Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer, Cochrane Database Syst Rev, 2014
Prostate Cancer Trialists’ Collaborative Group, 2000, Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, Lancet, 355, 1491, 10.1016/S0140-6736(00)02163-2
Nair, 2002, Early versus deferred androgen suppression in the treatment of advanced prostatic cancer, Cochrane Database Syst Rev, 3506
Hussain, 2013, Intermittent versus continuous androgen deprivation in prostate cancer, N Engl J Med, 368, 1314, 10.1056/NEJMoa1212299
Hussain, 2016, Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details, J Clin Oncol, 34, 280, 10.1200/JCO.2015.62.8065
Magnan, 2015, Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis, JAMA Oncol, 1, 1261, 10.1001/jamaoncol.2015.2895
Crook, 2012, Intermittent androgen suppression for rising PSA level after radiotherapy, N Engl J Med, 367, 895, 10.1056/NEJMoa1201546
Salonen, 2013, Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects, Eur Urol, 63, 111, 10.1016/j.eururo.2012.07.040
Clarke, 2019, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 30, 1992, 10.1093/annonc/mdz396
Gravis, 2016, Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized Phase 3 GETUG-AFU15 Trial, Eur Urol, 70, 256, 10.1016/j.eururo.2015.11.005
James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5
Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657
Vale, 2016, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, Lancet Oncol, 17, 243, 10.1016/S1470-2045(15)00489-1
Gravis, 2018, Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies, Eur Urol, 73, 847, 10.1016/j.eururo.2018.02.001
James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900
Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835
Armstrong, 2019, ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 37, 2974, 10.1200/JCO.19.00799
Armstrong, 2022, Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer, J Clin Oncol, 40, 1616, 10.1200/JCO.22.00193
Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307
Chi, 2021, Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study, J Clin Oncol, 39, 2294, 10.1200/JCO.20.03488
Agarwal, 2019, Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study, Lancet Oncol, 20, 1518, 10.1016/S1470-2045(19)30620-5
Fizazi, 2022, Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design, Lancet, 399, 1695, 10.1016/S0140-6736(22)00367-1
Smith, 2022, Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, 386, 1132, 10.1056/NEJMoa2119115
Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3
Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853
Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5
Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147
Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174
Rush, 2022, Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE Trial, J Clin Oncol, 40, 825, 10.1200/JCO.21.00728
Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026
Fendler, 2019, Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer, Clin Cancer Res, 25, 7448, 10.1158/1078-0432.CCR-19-1050
Smith, 2013, Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time, J Clin Oncol, 31, 3800, 10.1200/JCO.2012.44.6716
Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546
Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 378, 2465, 10.1056/NEJMoa1800536
Sternberg, 2020, Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 382, 2197, 10.1056/NEJMoa2003892
Fizazi, 2019, Darolutamide in nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 380, 1235, 10.1056/NEJMoa1815671
Oudard, 2021, Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy, Eur Urol Focus, 31
Smith, 2021, Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial, Eur J Cancer, 154, 138, 10.1016/j.ejca.2021.06.010
Tombal, 2021, The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials, Cancers (Basel), 13, 5872, 10.3390/cancers13235872
Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720
Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506
Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0
Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7
Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095
Shore, 2016, Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study, Lancet Oncol, 17, 153, 10.1016/S1470-2045(15)00518-5
Heidenreich, 2017, Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial, Eur Urol, 71, 534, 10.1016/j.eururo.2016.07.027
Penson, 2016, Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE Trial, J Clin Oncol, 34, 2098, 10.1200/JCO.2015.64.9285
Attard, 2018, Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment, J Clin Oncol, 36, 2639, 10.1200/JCO.2018.77.9827
Saad, 2021, Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study, Lancet Oncol, 22, 1541, 10.1016/S1470-2045(21)00402-2
Kellokumpu-Lehtinen, 2013, 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial, Lancet Oncol, 14, 117, 10.1016/S1470-2045(12)70537-5
Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 26, 242, 10.1200/JCO.2007.12.4008
Oudard, 2017, Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III trial-FIRSTANA, J Clin Oncol, 35, 3189, 10.1200/JCO.2016.72.1068
Eisenberger, 2017, Phase III study comparing a reduced dose of cabazitaxel (20mg/m(2)) and the currently approved dose (25mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA, J Clin Oncol, 35, 3198, 10.1200/JCO.2016.72.1076
de Wit, 2019, Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer, N Engl J Med, 381, 2506, 10.1056/NEJMoa1911206
Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791
Loriot, 2015, Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer, Eur J Cancer, 51, 1946, 10.1016/j.ejca.2015.06.128
Terada, 2017, Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration, Int J Urol, 24, 441, 10.1111/iju.13346
Miyake, 2017, Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer, Clin Genitourin Cancer, 15, e591, 10.1016/j.clgc.2016.12.015
Matsubara, 2018, Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer, Clin Genitourin Cancer, 16, 142, 10.1016/j.clgc.2017.09.008
Khalaf, 2019, Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial, Lancet Oncol, 20, 1730, 10.1016/S1470-2045(19)30688-6
Komura, 2019, Comparison of radiographic progression-free survival and PSA response on sequential treatment using abiraterone and enzalutamide for newly diagnosed castration-resistant prostate cancer: a propensity score matched analysis from multicenter cohort, J Clin Med, 8, 1251, 10.3390/jcm8081251
Lavaud, 2018, Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naïve prostate cancer in the GETUG-AFU 15 phase 3 trial, Eur Urol, 73, 696, 10.1016/j.eururo.2017.09.022
de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X
Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859
Mateo, 2018, Clinical outcome of prostate cancer patients with germline dna repair mutations: retrospective analysis from an international study, Eur Urol, 73, 687, 10.1016/j.eururo.2018.01.010
de Bono, 2020, Olaparib for metastatic castration-resistant prostate cancer, N Engl J Med., 10.1056/NEJMoa1911440
Clarke, 2018, Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, 19, 975, 10.1016/S1470-2045(18)30365-6
Beauval, 2018, Loco-regional treatment for castration-resistant prostate cancer: is there any rationale?. A critical review from the AFU-GETUG, Crit Rev Oncol Hematol, 122, 144, 10.1016/j.critrevonc.2017.12.012
Soubeyran, 2014, Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PLoS One, 9, 10.1371/journal.pone.0115060
Droz, 2014, Management of prostate cancer in older patients: updated recommendations of a working goup of the International Society of Geriatric Oncology, Lancet Oncol, 15, e404, 10.1016/S1470-2045(14)70018-X
Bechis, 2011, Impact of age at diagnosis on prostate cancer treatment and survival, J Clin Oncol, 29, 235, 10.1200/JCO.2010.30.2075
Albertsen, 2005, 20-year outcomes following conservative management of clinically localized prostate cancer, JAMA, 293, 2095, 10.1001/jama.293.17.2095
Lu-Yao, 2015, Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer, Eur Urol, 68, 805, 10.1016/j.eururo.2015.03.021
De Angelis, 2014, Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study, Lancet Oncol, 15, 23, 10.1016/S1470-2045(13)70546-1
Bellier, 2018, Incidence of prostate cancer and net survival by grade in a geriatric population: a population-based study in a French administrative entity from 1991 to 2013, Cancer Epidemiol, 56, 60, 10.1016/j.canep.2018.07.007
Daskivich, 2013, Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer, Ann Intern Med, 158, 709, 10.7326/0003-4819-158-10-201305210-00005
Vatandoust, 2018, Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry, BJU Int, 121, 48, 10.1111/bju.14228
Bratt, 2015, Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer, Eur Urol, 68, 53, 10.1016/j.eururo.2014.12.026
Anastasilakis, 2021, Denosumab discontinuation and the rebound phenomenon: a narrative review, J Clin Med, 10.3390/jcm10010152
James, 2022, Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476), Int J Cancer, 151, 422, 10.1002/ijc.34018
Fizazi, 2020, Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide, N Engl J Med, 383, 1040, 10.1056/NEJMoa2001342
Clarke, 2022, Abiraterone and olaparib for metastatic castration-resistant prostate cancer, NEJM Evid, 9, 3